Valuation: argenx SE

Market Cap 64.66B 55.36B 51.65B 47.39B 89.06B 6,187B 90.81B 613B 239B 3,100B 243B 237B 10,265B P/E 2026 *
36.8x
P/E 2027 * 29.7x
Enterprise Value 59.24B 50.72B 47.32B 43.42B 81.6B 5,668B 83.2B 561B 219B 2,841B 222B 218B 9,405B EV / Sales 2026 *
9.53x
EV / Sales 2027 * 7.4x
Free-Float
99.98%
Yield 2026 *
0.04%
Yield 2027 * 0.08%

Last Transcript: argenx SE

1 day+0.87%
1 week+16.32%
Current month+18.82%
1 month+17.71%
3 months+29.23%
6 months+23.36%
Current year+23.49%
1 week 723.4
Extreme 723.4
891.2
1 month 717.4
Extreme 717.4
891.2
Current year 568.4
Extreme 568.4
891.2
1 year 563.4
Extreme 563.4
891.2
3 years 271
Extreme 271
891.2
5 years 224.1
Extreme 224.1
891.2
10 years 12.5
Extreme 12.5
891.2
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
11/23/25 Fiscal year

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%+16.32%+58.35%+97.28% 63.98B
+2.38%+5.57%+86.02%+115.89% 72.21B
-4.27%-0.99%-3.38%+468.55% 28.53B
+3.63%+8.62%+66.69%+23.95% 25.07B
-1.97%+20.38%-0.37%-5.65% 28.42B
-0.51%+5.11%+41.27%-12.79% 20.04B
-1.79%-4.51%+241.26%+414.48% 18.19B
+1.81%+0.85%+16.89%+546.06% 15.96B
-1.29%+6.09%+41.81%+151.24% 13.48B
-2.17%+2.20%+333.02%+204.99% 12.63B
Average -0.33%+5.31%+88.16%+200.40% 29.85B
Weighted average by Cap. +0.27%+7.26%+72.91%+164.24%

Financials

2026 *2027 *
Net sales 6.22B 5.32B 4.97B 4.56B 8.56B 595B 8.73B 58.92B 22.97B 298B 23.35B 22.84B 987B 7.68B 6.58B 6.14B 5.63B 10.58B 735B 10.79B 72.79B 28.38B 368B 28.84B 28.21B 1,219B
Net income 1.87B 1.6B 1.49B 1.37B 2.58B 179B 2.63B 17.73B 6.91B 89.71B 7.02B 6.87B 297B 2.49B 2.13B 1.99B 1.83B 3.43B 238B 3.5B 23.62B 9.21B 119B 9.36B 9.15B 396B
Net Debt -5.42B -4.64B -4.33B -3.97B -7.46B -518B -7.61B -51.33B -20.01B -260B -20.34B -19.9B -860B -7.82B -6.7B -6.25B -5.73B -10.77B -748B -10.98B -74.12B -28.89B -375B -29.37B -28.73B -1,242B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-20 885.20 +0.87% 58,507
26-08-19 €877.60 +0.87% 94,376
26-08-18 €870.00 +1.73% 116,076
26-08-17 €855.20 +17.12% 158,662
26-08-14 €730.20 -3.21% 56,271
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,023.08USD
Average target price
1,091.41USD
Spread / Average Target
+6.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock